Hemos leído...

   ABRIL 2026

• Chiriboga K, Patel PN, Brunner HI.
  CAR T-cell therapy and indications for pediatric rheumatology: Structured overview of applications, risks, and considerations.
  Best Pract Res Clin Rheumatol. 2026 Apr 1:102143. doi: 10.1016/j.berh.2026.102143. Online ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/41927380/

• Locatelli F, De Benedetti F, Schett G.
  CAR-T cell therapy: "New black" for children with severe, refractory, B cell-mediated autoimmune disorders.
  Mol Ther. 2026 May 6;34(5):2568-2570. doi: 10.1016/j.ymthe.2026.04.023. Epub 2026 Apr 27.
  https://pubmed.ncbi.nlm.nih.gov/42049025/

• Brunner HI, Santiago M, Gottlieb B, Oliveira SK, Patel P, De Souza VA, Houghton K, Silva CA, Terreri MT, Cuttica R, Poyrazoglu MH, Wasserman HM, Saul M, Soderstrom CI, Diehl A, Vranic I, Yndestad A, Mortezavi M, Lovell DJ, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
  Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis.
  Ann Rheum Dis. 2026 Apr 30:S0003-4967(26)00216-5. doi: 10.1016/j.ard.2026.03.030. Online ahead of print.PMID: 42067428
  https://pubmed.ncbi.nlm.nih.gov/42067428/

   MARZO 2026

• Santosa A, Tan TC.
  CAR-T cell therapy for treatment-refractory rheumatic autoimmune diseases: a systematic review of clinical outcomes and safety profiles.
  RMD Open. 2026 Mar 4;12(1):e006417. doi: 10.1136/rmdopen-2025-006417.
  https://pubmed.ncbi.nlm.nih.gov/41781158/

• Suresh N, Spoorthy Raj DR, Patil H, Arora D, Mamadapur M.
  Hematopoietic Stem Cell Transplantation in Rheumatic Diseases.
  Int J Rheum Dis. 2026 Mar;29(3):e70604. doi: 10.1111/1756-185x.70604.
  https://pubmed.ncbi.nlm.nih.gov/41821208/

• Weßling J, Leiskau C, Dressler F, Klemann C.
  Methotrexate Therapy in Juvenile Idiopathic Arthritis: No Clinically Relevant Pulmonary Impairment but Frequent Transient Liver Enzyme Elevations in a Longitudinal Single-Center Pediatric Cohort of 274 Children Over 30 Years.
  ACR Open Rheumatol. 2026 Mar;8(3):e90000. doi: 10.1002/acr2.90000.
  https://pubmed.ncbi.nlm.nih.gov/41873148/

• Queiro R, Braña I, Alvarez P, Loredo M, Pardo E, Burger S.
  Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation.
  Expert Rev Pharmacoecon Outcomes Res. 2026 Mar;26(3):419-427. doi: 10.1080/14737167.2026.2629351
  https://pubmed.ncbi.nlm.nih.gov/41657049/

   FEBRERO 2026

• Scott C, Slamang W, Dushnicky M, Hause E, Faleye A, Furia F, Cuevas OA, Hadef D, Munro J, Nzabonimpa C, Foster H, Migowa A; Paediatric Global Task Force for Musculoskeletal Health.
  The challenges and opportunities for equitable global access to medications for paediatric rheumatology in low-to middle-income countries: a review on behalf of the Paediatric Global Task Force for Musculoskeletal Health.
  Arthritis Res Ther. 2026 Feb 27;28(1):79.
  https://pubmed.ncbi.nlm.nih.gov/41761340/

   ENERO 2026

• He L, Zhang D, Gapud EJ, Peng S, Belen O, Sahajwalla C, et al.
  Approval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective.
  J Clin Pharmacol. 2026 Jan;66(1):e70104.
  https://pubmed.ncbi.nlm.nih.gov/41014542/
• Müller F, Hagen M, Wirsching A, Kharboutli S, Aigner M, Völkl S, et al.
  CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.
  Nat Med. 2026 Jan 7.
  https://pubmed.ncbi.nlm.nih.gov/41501497/ 
• Shahin MM, Gorell ES, Iqneibi M, Sun Q, Brunner HI, Hellmann J, et al.
  Characterization of TNF-Alpha Inhibitor Induced Paradoxical Psoriasiform Dermatitis at a Single Center via Retrospective Chart Review.
  Pediatr Dermatol. 2026 Jan-Feb;43(1):84-87.
  https://pubmed.ncbi.nlm.nih.gov/41611249/
• Bräm DS, Gotta V, Koch G, Golhen K, Woerner A, Atkinson A, et al.
  Evaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation study.
  Pediatr Rheumatol Online J. 2026 Jan 22.
  https://pubmed.ncbi.nlm.nih.gov/41572321/
• Pang RX, Miller MR, Park H, Wells S, Demirkaya E, Rieder MJ, et al.
  Body mass index associated with glucocorticoid-related weight gain in children with rheumatic disease on high-dose prednisone.
  Clin Exp Rheumatol. 2026 Jan;44(1):156-160.
  https://pubmed.ncbi.nlm.nih.gov/41328600/
• Crauwels H, Ringold S, Howard S, Van Hartingsveldt B, Smith V, Jett M, et al.
  Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data.
  Paediatr Drugs. 2026 Jan;28(1):69-81.
  https://pubmed.ncbi.nlm.nih.gov/41152645/

  DICIEMBRE 2025

• Ciurtin C, Sparchez M, Elephtheriou D, Brogan P
  The evolving landscape of rheumatic drugs and their indications in paediatric and adolescent care
  Rheumatology (Oxford). 2025 Dec 1;64(12):6048–6070
  https://pubmed.ncbi.nlm.nih.gov/40845184/

  OCTUBRE 2025

• Meister S, Georgi M, Hügle B, Haas JP; Participating Centers of the Society for Pediatric and Adolescent Rheumatology (GKJR)
  Treatment after intra-articular corticosteroid injection in juvenile idiopathic arthritis: a survey within the German Society for Pediatric and Adolescent Rheumatology.
  Pediatr Rheumatol Online J. 2025 Oct 2;23(1):96.
  https://pubmed.ncbi.nlm.nih.gov/41039572/

• Gallizzi R, Dipasquale RF, Mendicino A, Ferrillo M, Longo UG, Concolino D, Ammendolia A, de Sire A.
  Effectiveness of steroid intra-articular injections on functioning in children and adolescents affected by juvenile idiopathic arthritis: a systematic review.
  Eur J Pediatr. 2025 Oct 20;184(11):708.
  https://pubmed.ncbi.nlm.nih.gov/41114805/

• Crauwels H, Ringold S, Howard S, Van Hartingsveldt B, Smith V, Jett M, Baguet T, Adamson E, Chakravarty SD, Leu JH.
  Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data.
  Paediatr Drugs. 2025 Oct 28
  https://pubmed.ncbi.nlm.nih.gov/41152645/

• Ruperto N, Lovell DJ, Synoverska O, Abud-Mendoza C, Spindler A, Vyzhga Y, et al; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
  Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial.
  ACR Open Rheumatol. 2025 Oct;7(10):e70097. 
  https://pubmed.ncbi.nlm.nih.gov/41058253/

•  Brunner HI, Alexeeva E, Bandeira M, Carrasco R, Chaitow J, Chiraseveenuprapund P, et al; Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG).
  Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase III, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial.
  Arthritis Rheumatol. 2025 Oct 31.
  https://pubmed.ncbi.nlm.nih.gov/41169192/

 JULIO 2025

• Johnson T, Naz H, Taylor V, Farook S, Hofmann G, Harbacheck K, et al.
  Incidence and Risk Factors for Steroid-associated Osteonecrosis in Children and Adolescents: A Systematic Review of the Literature.
  J Pediatr Orthop. 2025 Jul 1;45(6):337-347. doi: 10.1097/BPO.0000000000002919.
  https://pubmed.ncbi.nlm.nih.gov/40078093/

• Huang J, Teh KL, Chen C, Das L, Arkachaisri T.
  Efficacy and safety of anti-Tumor Necrosis Factor-α biosimilars in Juvenile Idiopathic Arthritis - a systematic review and meta-analysis.
  Semin Arthritis Rheum. 2025 Jul 16;74:152792. doi: 10.1016/j.semarthrit.2025.152792. Epub ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/40714372/

• Piao Y, Xu X, Yao X, Li Y, Sun Y, Han T, Wang X, Mao H.
  Paradoxical psoriasis in pediatric tumor necrosis factor-α inhibitor therapy database.
  Pediatr Res. 2025 Jul 23. doi: 10.1038/s41390-025-04305-5. Epub ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/40702205/

• Civino A, Diomeda F, Burrone M, Natoli V, Ravelli A.
  Update on Biologic Therapy in Juvenile Idiopathic Arthritis: A Five-year Narrative Review.
  Biologics. 2025 Jul 23;19:425-441. doi: 10.2147/BTT.S486359.
  https://pubmed.ncbi.nlm.nih.gov/40717835/

• Atamyıldız Uçar S, Sözeri B.
  Clinical use of biologics in juvenile idiopathic arthritis: lessons learned from real-world studies.
  Expert Opin Biol Ther. 2025 Jul 18:1-12. doi: 10.1080/14712598.2025.2536351. Epub ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/40668062/

• Al-Mayouf SM, Alenzi F, Khamaj Y, Aljazaeri S, Fouda L, AlSaleem A, Alhuthil R.
  Effectiveness and safety of bisphosphonates in inflammatory bone disorders: a systematic review.
  Clin Exp Rheumatol. 2025 Jul;43(7):1354-1362. doi: 10.55563/clinexprheumatol/y0ve3b.
  https://pubmed.ncbi.nlm.nih.gov/40153323/

 JUNIO 2025

• Scherlinger M, Nocturne G, Radic M, Launay D, Richez C, Bousso P et al.
  CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
  Lancet Rheumatol. 2025 Jun;7(6):e434-e447. doi: 10.1016/S2665-9913(24)00377-1.
  https://pubmed.ncbi.nlm.nih.gov/40157379/

• Pellico MR, Pandolfi M, Amati A, Iannone C, Germinario S, Costi S et al.
  The effectiveness and safety of rituximab in juvenile idiopathic arthritis: Hints from the ITHACA monocentric registry.
  Semin Arthritis Rheum. 2025 Jun 18;74:152774. doi: 10.1016/j.semarthrit.2025.152774. Epub ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/40561558/

• Ohta R, Horinishi Y, Sano C, Ichinose K.
  Efficacy of Mycophenolate Mofetil in Treating Skin Fibrosis in Systemic Sclerosis: A Systematic Review and Meta-Analysis.
  J Clin Med. 2025 Jun 12;14(12):4187. doi: 10.3390/jcm14124187.
  https://pubmed.ncbi.nlm.nih.gov/40565931/

• Pottackal G, Travis J, Nie L, Chiu R, Neuner R, Levin G, Niu J, Marathe A, Mulugeta LY, Nikolov NP.
  Application of Bayesian statistics to support approval of intravenous belimumab in children with systemic lupus erythematosus in the United States.
  Lupus. 2025 Aug;34(9):943-952. doi: 10.1177/09612033251349930.
  https://pubmed.ncbi.nlm.nih.gov/40577570/

 

 ABRIL 2025

• Rüegg L, Pluma A, Hamroun S, Cecchi I, Perez-Garcia LF, Anderson PO, et al.
  EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update
  Ann Rheum Dis. 2025 Apr 25:S0003-4967(25)00818-0. doi: 10.1016/j.ard.2025.02.023. Online ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/40287311/

MARZO 2025

• Gezgin Yildirim D, Orulluoglu EY, Yildiz C, Acari C, Dundar HA, Akaci O, et al.
  Cyclophosphamide treatment with a comparison in both pediatric rheumatology and pediatric nephrology practices.
  Pediatr Rheumatol Online J. 2025 Mar 11;23(1):24. doi: 10.1186/s12969-025-01080-9.
  https://pubmed.ncbi.nlm.nih.gov/40069880/

• Bellando-Randone S, Wilhalme H, Bruni C, Czirjak L, Distler O, Allanore Y, et al; and the EUSTAR collaborators.
  The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort.
  Arthritis Res Ther. 2025 Mar 27;27(1):66. doi: 10.1186/s13075-025-03476-0.
  https://pubmed.ncbi.nlm.nih.gov/40148996/

• Tepecik T, Zöngör M, Gedik E.
  Do I-PRF adjuvant injections in TMJ arthrocentesis have acumulative physiological effect? A retrospective cohort study.
  BMC Oral Health. 2025 Mar 27;25(1):445. doi: 10.1186/s12903-025-05824-7.
  https://pubmed.ncbi.nlm.nih.gov/40148835/

FEBRERO 2025

• Li YX, Dong C, Chen BS, Huo AP.
  Therapeutic Potential of Janus Kinase Inhibitors in Juvenile Idiopathic Arthritis.
  Int J Rheum Dis. 2025 Feb;28(2):e70134.
  https://pubmed.ncbi.nlm.nih.gov/39953765/

• Li Y, Huang B, Andorf S, Yue X, Lovell DJ, Brunner HI.
  Comparative Effectiveness and Safety of the JAK Inhibitors and Biologic Disease-Modifying Antirheumatic Drugs in Treating Children With Nonsystemic Juvenile Idiopathic Arthritis: A Bayesian Meta-Analysis of Randomized Controlled Trials.
  ACR Open Rheumatol. 2025 Feb;7(2):e11788.
  https://pubmed.ncbi.nlm.nih.gov/39964338/

ENERO 2025

• Gicchino MF, Capasso G, Amodio A, Miraglia Del Giudice E, Olivieri AN, Di Sessa A.
  Biosimilars Versus Originators in Children With Juvenile Idiopathic Arthritis: A Real-World Experience.
  J Pediatr Health Care. 2025 Jan-Feb;39(1):88-92. doi: 10.1016/j.pedhc.2024.08.003. Epub 2024 Aug 30.
  https://pubmed.ncbi.nlm.nih.gov/39217527/

• De Rose DU, Campi F, Maddaloni C, Ronci S, Caoci S, Savarese I, Bersani I, Ronchetti MP, Auriti C, Capolupo I, Merli P, Insalaco A, De Benedetti F, Dotta A.
  Off-Label Use of Anakinra in Inflammatory Conditions in Neonates and Infants Up to 3 Months of Age: A Case Series and a Review of the Literature.
  Paediatr Drugs. 2025 Jan 13. doi: 10.1007/s40272-024-00679-x. Epub ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/39804459/

DICIEMBRE 2024

• Shishov M, Weiss PF, Levy DM, Chang JC, Angeles-Han ST, Ogbu EA et al.
  25 Years of Biologics For The Treatment of Pediatric Rheumatic Diseases - Advances in Prognosis and Ongoing Challenges.
  Arthritis Care Res (Hoboken). 2024 Dec 9. doi: 10.1002/acr.25482. Epub ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/39651592/

• Yıldız Ç, Küçükali B, C SSB, Şenol PE, Kutlar M, Belder N et al.
  Intraarticular corticosteroid injections in pediatric rheumatology: insights from specialists.
  Eur J Pediatr. 2024 Dec;183(12):5405-5410. doi: 10.1007/s00431-024-05817-8. Epub 2024 Oct 14.
  https://pubmed.ncbi.nlm.nih.gov/39397078/

• Balay-Dustrude E, Fennell J, Baszis K, Goh YI, Horton DB, Lee T et al.
  Approaches and outcomes of adalimumab discontinuation in patients with well-controlled inflammatory arthritis: a systematic search and review.
  Pediatr Rheumatol Online J. 2024 Dec 30;22(1):112. doi: 10.1186/s12969-024-01046-3.
  https://pubmed.ncbi.nlm.nih.gov/39734203/

• Qian Y, Schlachter L, Eckert D, Stodtmann S, Shmagel A, Peng Y, Liu W, Mohamed MF.
  Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure-Response Models, and Real-World Patient Data.
  Clin Pharmacol Ther. 2024 Dec;116(6):1635-1645. doi: 10.1002/cpt.3441. Epub 2024 Sep 29.
  https://pubmed.ncbi.nlm.nih.gov/39344158/

• Garcia-Silva J, Silva-Ramirez B, Villarreal-Treviño AV, Mata-Tijerina V, Rubio-Perez NE, Garcia-Rodriguez F.
  Relationship between SLCO1B1 polymorphisms and methotrexate intolerance in Mexican children with juvenile idiopathic arthritis.
  Clin Rheumatol. 2024 Dec;43(12):3849-3853. doi: 10.1007/s10067-024-07221-x. Epub 2024 Nov 4.
  https://pubmed.ncbi.nlm.nih.gov/39489878/

 

NOVIEMBRE 2024

• Brunner HI, Shmagel A, Horneff G, Foeldvari I, Antón J, Ramanan AV, Qian Y, Unnebrink K, Hao S, Camp HS, Khan N, Liu W, Mohamed MF.
  Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients with Polyarticular-Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-label, Phase 1 Trial.
  Arthritis Care Res (Hoboken). 2024 Nov 14. doi: 10.1002/acr.25465. Epub ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/39542836/

• Mayo-Juanatey A, Valera-Ribera C, Andújar-Brazal P, León-Torralba P, Vázquez-Gómez I, Alegre-Sancho JJ.
  Anifrolumab as maintenance therapy in a patient with haemophagocytic lymphohistiocytosis secondary to systemic lupus erythematosus.
  Clin Exp Rheumatol. 2024 Nov 29. doi: 10.55563/clinexprheumatol/xmgjcl. Online ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/39625834/

• Hsiao EC, Pacifici M.
  Palovarotene (Sohonos), a synthetic retinoid for reducing new heterotopic ossification in fibrodysplasia ossificans progressiva: history, present, and future.
  JBMR Plus. 2024 Nov 19;9(1):ziae147. doi: 10.1093/jbmrpl/ziae147. 
  https://pubmed.ncbi.nlm.nih.gov/39677926/

OCTUBRE 2024

• Côte G, Quartier P, Belot A, Melki I, Hentgen V, Merlin E.
  The place of JAK inhibitors in systemic juvenile idiopathic arthritis with lung disease (SJIA-LD): French experience
  Rheumatology (Oxford). 2024 Oct 24:keae589. doi: 10.1093/rheumatology/keae589. Online ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/39447041/

• Kretzschmar G, Páez LP, Tan Z, Wang J, Gonzalez L, Mugabo CH, et al.
  Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies.
  J Clin Immunol. 2024 Oct 23;45(1):31. doi: 10.1007/s10875-024-01826-2.
  https://pubmed.ncbi.nlm.nih.gov/39441221/

• Metko D, Mehta S, Geng R, Mufti A, Yeung J.
  Tocilizumab for the Treatment of Refractory Morphea: A Systematic Review.
  J Cutan Med Surg. 2024 Oct 25:12034754241291045. doi: 10.1177/12034754241291045. Online ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/39450622/

SEPTIEMBRE 2024

• Ramakrishna C, Mason A, Edwards CJ.
  Tyrosine kinase 2 inhibitors in autoimmune diseases.
  Autoimmun Rev. 2024 Sep 28:103649. doi: 10.1016/j.autrev.2024.103649. Online ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/39349269/
• Vojinović J, Foeldvari I, Dehoorne J, Panaviene V, Susic G, Horneff G, et al; Paediatric Rheumatology International Trials Organisation (PRINTO).
  Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis.
  Rheumatol Ther. 2024 Sep 12. doi: 10.1007/s40744-024-00703-z. Online ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/39264536/
• Kundnani NR, Levai MC, Popa MD, Borza C, Iacob M, Mederle AL, Blidisel A.
  Biologics in Systemic Lupus Erythematosus: Recent Evolutions and Benefits.
  Pharmaceutics. 2024 Sep 6;16(9):1176. doi: 10.3390/pharmaceutics16091176.
  https://pubmed.ncbi.nlm.nih.gov/39339212/
• Guo Y, Li J, Hu R, Tan J, Luo H, Zhang Z, Luo Q, Xia X.
  Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis.
  BMC Psychiatry. 2024 Sep 4;24(1):596. doi: 10.1186/s12888-024-06037-y.
  https://pubmed.ncbi.nlm.nih.gov/39232752/

• Maccora I, dell'Anna MP, Vannacci A, Simonini G.
  Safety evaluations of adalimumab for childhood chronic rheumatic diseases.
  Expert Opin Drug Saf. 2020 May 14:1-11.
  https://doi.org/10.1080/14740338.2020.1763300
• Sag E, Bayindir Y, Adiguzel A, Demir S, Bilginer Y, Aytac S, Ozen S.
  Colchicine and Leukopenia: Clinical Implications.
  J Pediatr. 2020 May 13:S0022-3476(20)30444-3.
  https://doi.org/10.1016/j.jpeds.2020.03.065
• Fiehn C, Ness T, Weseloh C, Specker C, Hadjiski D, Detert J, Krüger K; DGRh Kommission Pharmakotherapie
  Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review.
  Z Rheumatol. 2020 Mar 31. doi: 10.1007/s00393-020-00785-4. Online ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/32236844
• Cuevas OA, Hedrich CM.
  Biosimilars in pediatric rheumatology and their introduction into routine care
  Clin Immunol. 2020 Apr 30:108447. doi: 10.1016/j.clim.2020.108447. Online ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/32360950
• Cron RQ, Chatham WW.
  The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic.
  J Rheumatol. 2020 Apr 25:jrheum.200492. doi: 10.3899/jrheum.200492. Online ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/32335514
• Filocamo G, Minoia F, Carbogno S, Costi S, Romano M, Cimaz R; Pediatric Rheumatology Group of the Milan Area.
  Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs.
  J Rheumatol. 2020 Apr 25:jrheum.200483. doi: 10.3899/jrheum.200483. Online ahead of print.
  https://pubmed.ncbi.nlm.nih.gov/32335512

• Cimaz R, Maioli G, Calabrese G.
  Current and emerging biologics for the treatment of juvenile idiopathic arthritis.Expert Opin Biol Ther. 2020 Mar 2:1-16. doi: 10.1080/14712598.2020.1733524. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32116038

• Elewaut D, Braun J, Anderson JK, Arikan D, Chen S, Hojnik M, De Craemer AS, Curtis JR.
  Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases.
  Arthritis Care Res (Hoboken). 2020 Feb 26. doi: 10.1002/acr.24175. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32100944
• Ho ACH, Wong SN, Leung LCK, Chan WKY, Chong PCY, Tse NKC, Yeung RHM, Kong SY, Lee KP.
  Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement.
  Hong Kong Med J. 2020 Feb;26(1):56-65. doi: 10.12809/hkmj198195.
  https://www.ncbi.nlm.nih.gov/pubmed/32077861
• Kahlenberg JM, Billi AC, Eyerich K, Gudjonsson JE.
  Biologics in the treatment of skin and rheumatologic diseases.
  J Allergy Clin Immunol. 2020 Feb 26. pii: S0091-6749(20)30270-0. doi: 10.1016/j.jaci.2020.02.017.
  https://www.ncbi.nlm.nih.gov/pubmed/32112793
• Smits RM, Veldhuijzen DS, van Middendorp H, Hissink Muller PCE, Armbrust W, Legger E, Wulffraat NM, Evers AWM.
  Pharmacological conditioning for juvenile idiopathic arthritis: a potential solution to reduce methotrexate intolerance.
  Pediatr Rheumatol Online J. 2020 Feb 7;18(1):12. doi: 10.1186/s12969-020-0407-5.
  https://www.ncbi.nlm.nih.gov/pubmed/32033577

• Zabotti A, Goletti D, Lubrano E, Cantini F.
  The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis.
  Expert Opin Drug Saf. 2020 Jan;19(1):69-82
  https://www.ncbi.nlm.nih.gov/pubmed/31847608
• Tektonidou MG.
  JAK inhibitors: promising for a wider spectrum of autoimmune diseases?
  Lancet. 2019 Dec 7;394(10214):2047-2048
  https://www.ncbi.nlm.nih.gov/pubmed/31732181
• Koç R, Sönmez HE, Çakan M, Karadağ ŞG, Tanatar A, Çakmak F, Aktay Ayaz N.
  Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center.
  Rheumatol Int. 2019 Dec 21. doi: 10.1007/s00296-019-04498-z.
  https://www.ncbi.nlm.nih.gov/pubmed/31865444
• Noguera-Julian A, Calzada-HernÁndez J, Brinkmann F, Basu Roy R, Bilogortseva O, Buettcher M, Carvalho I, Chechenyeva V, Falcon L, Goetzinger F, Guerrero-Laleona C, Hoffmann P, Jelusic M, Niehues T, Ozere I, Shackley F, Suciliene E, Welch SB, Schölvinck EH, Ritz N, Tebruegge M.
  Tuberculosis disease in children and adolescents on therapy with anti-tumor necrosis factor-alpha agents: a collaborative, multi-centre ptbnet study.
  Clin Infect Dis. 2019 Dec 4. pii: ciz1138. doi: 10.1093/cid/ciz1138
  https://www.ncbi.nlm.nih.gov/pubmed/31796965

• Buckley LH, Xiao R, Perman MJ, Grossman AB, Weiss PF.
  Psoriasis Associated with Tumor Necrosis Factor-Alpha Inhibitors in Children with Inflammatory Diseases.
  Arthritis Care Res (Hoboken). 2019 Oct 23. doi: 10.1002/acr.24100. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/31646743
• Park EH, Lee EY, Shin K, Kim HA.
  Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review
  Rheumatol Int. 2019 Oct 9. doi: 10.1007/s00296-019-04456-9. [Epub ahead of print] Review.
  https://www.ncbi.nlm.nih.gov/pubmed/31598752
• Renton WD, Leveret H, Guly C, Smee H, Leveret J, Ramanan AV.
  Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
  Pediatr Rheumatol Online J. 2019 Oct 4;17(1):67. doi: 10.1186/s12969-019-0366-x
  https://www.ncbi.nlm.nih.gov/pubmed/31585539

• Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P.
  JAK inhibitors for the treatment of autoimmune and inflammatory diseases.
  Autoimmun Rev. 2019 Sep 11:102390. doi: 10.1016/j.autrev.2019.102390. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31520803
• Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz HI, Minden K, Onel K, Zemel L, Martin A, Koné-Paut I, Siamopoulou-Mavridou A, Silva CA, Porter-Brown B, Bharucha KN, Brunner HI, De Benedetti F; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric RheumatologyCollaborative Study Group (PRCSG).
  Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis.
  J Rheumatol. 2019 Sep;46(9):1117-1126. doi: 10.3899/jrheum.180795. Epub 2019 Mar 1.
  https://www.ncbi.nlm.nih.gov/pubmed/30824645
• Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW.
  Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.
  Arthritis Rheumatol. 2019 Sep 18. doi: 10.1002/art.41121. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31532077

• Sota J, Rigante D, Ruscitti P, Insalaco A, Sfriso P, de Vita S, Cimaz R, Lopalco G, Emmi G, La Torre F, Fabiani C, Olivieri AN, Cattalini M, Cammelli D, Gallizzi R, Alessio M, Manna R, Viapiana O, Frassi M, Pardeo M, Maier A, Salvarani C, Talarico R, Mosca M, Colafrancesco S, Priori R, Maggio MC, Gaggiano C, Grosso S, De Benedetti F, Vitale A, Giacomelli R, Cantarini L.
  Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease.
  Front Pharmacol. 2019 Aug 23;10:918. doi: 10.3389/fphar.2019.00918. eCollection 2019.
  https://www.ncbi.nlm.nih.gov/pubmed/31507416
• Soyer O, Demir S, Bilginer Y, Batu ED, Sonmez EH, Arıcı SZ, Şahiner ÜM, Sekerel BE, Ozen S.
  Severe Hypersensitivity Reactions to Biological Drugs in Children with Rheumatic Diseases.
  Pediatr Allergy Immunol. 2019 Aug 16. doi: 10.1111/pai.13114.
  https://www.ncbi.nlm.nih.gov/pubmed/31419311
• Mallalieu NL, Wimalasundera S, Hsu JC, Douglass W, Wells C, Penades IC, Cuttica R, Huppertz HI, Joos R, Kimura Y, Milojevic D, Rosenkranz M, Schikler K, Constantin T, Wouters C.
  Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
  Pediatr Rheumatol Online J. 2019 Aug 22;17(1):57.
  https://www.ncbi.nlm.nih.gov/pubmed/31438986

•  Verstegen RHJ, McMillan R, Feldman BM, Ito S, Laxer RM
  Towards therapeutic drug monitoring of TNF inhibitors for children with juvenile idiopathic arthritis: a scoping review.
  Rheumatology (Oxford). 2019 Jul 23. pii: kez285. doi: 10.1093/rheumatology/kez285. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/31335941

• Shenoi S, Nanda K, Schulert GS, Bohnsack JF, Cooper AM, Edghill B, Gillispie-Taylor MC, Goldberg B, Halyabar O, Mason TG, Ronis T, Schneider R, Vehe RK, Onel K; CARRA Systemic Juvenile Idiopathic Arthritis Workgroup.
  Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey.
  Pediatr Rheumatol Online J. 2019 Jul 22;17(1):48.
  https://www.ncbi.nlm.nih.gov/pubmed/31331351

• Schanberg LE, Ramanan AV, De Benedetti F, Beukelman T, Eakin GS, Del Gaizo V et al.
  Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis.
  Arthritis Rheumatol. 2019 Jul 16. doi: 10.1002/art.41043. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/31313532
• Hand RM, Salman S, Newall N, Vine J, Page-Sharp M, Bowen AC, et al.
  A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease: new insights for improved secondary prophylaxis strategies.
  J Antimicrob Chemother. 2019 Jul 1;74(7):1984-1991.
  https://www.ncbi.nlm.nih.gov/pubmed/30989171

• Groth D, Perez M, Treat JR, Castelo-Soccio L, Nativ S, Weiss PF, Lapidus S, Perman MJ.
  Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
  Pediatr Dermatol. 2019 Jun 25. doi: 10.1111/pde.13859. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/31240749
• Diener C, Horneff G.
  Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review.
  Expert Opin Drug Saf. 2019 Jun 26:1-14. doi: 10.1080/14740338.2019.1632288
  https://www.ncbi.nlm.nih.gov/pubmed/31204508

• Pan S, Yu H, Surti A, Cheng I, Marks SD, Brogan PA, Eleftheriou D, Standing JF.
  Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases.
  Br J Clin Pharmacol. 2019 Apr 26. doi: 10.1111/bcp.13970. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/31026092

• Doeleman MJH, van Maarseveen EM, Swart JF.
  Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis.
  Rheumatology (Oxford). 2019 Feb 26. pii: kez030. doi: 10.1093/rheumatology/kez030. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/30809664
• Leu JH, Adedokun OJ, GarganoC, Hsia EC, Xu Z, Shankar G
  Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
  Rheumatology (Oxford) 2019 Mar; 58(3):441–446
  https://doi.org/10.1093/rheumatology/key309

• Wilkinson MGL, Rosser EC.
  B Cells as a Therapeutic Target in Paediatric Rheumatic Disease.
  Front Immunol. 2019 Feb 14;10:214. doi: 10.3389/fimmu.2019.00214. eCollection 2019.
  https://www.ncbi.nlm.nih.gov/pubmed/30837988
• Doeleman MJH, van Maarseveen EM, Swart JF.
  Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis.
  Rheumatology (Oxford). 2019 Feb 26. pii: kez030. doi:
  10.1093/rheumatology/kez030. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/30809664
• Aydin V, Akici A, Isli F, Aksoy M, Aydin M, Gursoz H.
  Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study.
  J Clin Pharm Ther. 2019 Feb 14. doi: 10.1111/jcpt.12814. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/30763469
• Nijhuis L, Peeters JGC, Vastert SJ, van Loosdregt J.
  Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis.
  Front Immunol. 2019 Feb 7;10:151. doi: 10.3389/fimmu.2019.00151. eCollection 2019.
  https://www.ncbi.nlm.nih.gov/pubmed/30792714

• Nagy A, Mátrai P, Hegyi P, Alizadeh H, Bajor J, Czopf L, Gyöngyi Z, Kiss Z, Márta K, Simon M, Szilágyi ÁL, Veres G, Mosdósi B.
  The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis.
  Pediatr Rheumatol Online J. 2019 Jan 18;17(1):4. doi: 10.1186/s12969-019-0305-x.
  https://www.ncbi.nlm.nih.gov/pubmed/30658717

• Abreu P, Ávila-Pedretti G, Morel Z, Acosta MI, Cabrera-Villalba S, Melgarejo P, Franco M, Delgadillo P, Román L, Elizaur JG, Paredes E, Cordovilla DO, Palleiro D, Albanese M, Mazzoleni J.
  Seguridad y supervivencia de las terapias biológicas: Primer informe del registro paraguayo-uruguayo de acontecimientos adversos con terapias biológicas. Biobadaguay.
  Reumatol Clin. 2018 Dec 27. pii: S1699-258X(18)30189-X. doi: 10.1016/j.reuma.2018.08.009. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/30595458
• Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Е, Panaviene V, Bader-Meunier B, Anton J, Nielsen S, De Benedetti F, Kamphuis S, Staņēviča V, Tracahana M, Ailioaie LM, Tsitsami E, Klein A, Minden K21,22, Foeldvari I, Haas JP, Klotsche J, Horne AC, Consolaro A, Bovis F, Bagnasco F, Pistorio A, Martini A, Wulffraat N, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO), BiKeR and the board of the Swedish Registry.
  Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
  Arthritis Res Ther. 2018 Dec 27;20(1):285. doi: 10.1186/s13075-018-1780-z.
  https://www.ncbi.nlm.nih.gov/pubmed/30587248
• Jung JY, Kim MY, Suh CH, Kim HA.
  Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review.
  Pediatr Rheumatol Online J. 2018 Dec 14;16(1):79. doi: 10.1186/s12969-018-0296-z.
  https://www.ncbi.nlm.nih.gov/pubmed/30547812
• Lyseng-Williamson KA.
  Anakinra in Still's disease: a profile of its use.
  Drugs Ther Perspect. 2018;34(12):543-553. doi: 10.1007/s40267-018-0572-5. Epub 2018 Oct 31.
  https://www.ncbi.nlm.nih.gov/pubmed/30546251

• Aygun D, Sahin S, Adrovic A, Barut K, Cokugras H, Camcıoglu Y, Kasapcopur O.
  The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study.
  Clin Rheumatol. 2018 Nov 17. doi: 10.1007/s10067-018-4367-9. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/30448935
• Klein A, Becker I, Minden K, Foeldvari I, Haas JP, Horneff G
  Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
  Scand J Rheumatol. 2018 Nov 9:1-10. doi: 10.1080/03009742.2018.1488182. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/30411654

• Aeschlimann FA, Chong SL, Lyons TW, Beinvogl BC, Góez-Mogollón LM, Tan S, Laxer RM.
  Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analyses
  J Pediatr. 2018 Oct 11. pii: S0022-3476(18)31239-3. doi: 10.1016/j.jpeds.2018.08.065. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/30318371
• Keppeke LF, Molina J, Miotto E Silva VB, Terreri MTSELRA, Keppeke GD, Schoen TH, Len CA.
  Psychological characteristics of caregivers of pediatric patients with chronic rheumatic disease in relation to treatment adherence.
  Pediatr Rheumatol Online J. 2018 Oct 12;16(1):63. doi: 10.1186/s12969-018-0280-7.
  https://www.ncbi.nlm.nih.gov/pubmed/30314523

• Hunter H.
  Etanercept or adalimumab: which is a better biological therapy for juvenile idiopathic arthritis?
  Arch Dis Child. 2018 Sep 27. pii: archdischild-2018-315528. doi: 10.1136/archdischild-2018-315528. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/30262509
• Cabrera N, Lega JC, Kassai B, Wouters C, Kondi A, Cannizzaro E, Woerner A, Chausset A, Roethlisberger S, Jeanneret C, Aeschlimann F, Malik S, Duquesne A, Kaiser D, Higel L, Maes A, Berthet G, Hentgen V, Kone-Paut I, Belot A, Hofer M.
  Safety of biological agents in paediatric rheumatic diseases: a real-life multicenter retrospective study using the JIRcohorte database.
  Joint Bone Spine. 2018 Sep 7. pii: S1297-319X(18)30283-5. doi: 10.1016/j.jbspin.2018.08.003. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/30201476
• Nieto-González JC, Monteagudo I
  Estado actual del tratamiento con infiltraciones intraarticulares en la artritis idiopática juvenil
  Reumatol Clin. 2018 Sep 19. pii: S1699-258X(18)30174-8. doi: 10.1016/j.reuma.2018.07.015. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/30243614
• Ruiz-Medrano J, Díaz-Valle D, Cuiña R, Gegúndez JA, Chhablani J, Majumder PD, Gutierrez-Bonet R.
  The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative.
  J Fr Ophtalmol. 2018 Sep 11. pii: S0181-5512(18)30282-1. doi: 10.1016/j.jfo.2018.02.006. [Epub ahead of print] 
  
  https://www.ncbi.nlm.nih.gov/pubmed/30217605
• Chi H, Teng J, Yang C, Su Y.
  Bone tumors developed in patients with juvenile inflammatory arthritis after anti-TNFα therapy.
  Immunotherapy. 2018 Sep;10(12):1033-1039.
  https://www.ncbi.nlm.nih.gov/pubmed/30185135

• Randell RL, Adams AV, Van Mater H.
  Tocilizumab in Refractory Autoimmune Encephalitis: A Series of Pediatric Cases.
  Pediatr Neurol. 2018 Aug 3. pii: S0887-8994(18)30366-7. doi: 10.1016/j.pediatrneurol.2018.07.016. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/30177347
• Nijhof LN, Nap-van der Vlist MM, van de Putte EM, van Royen-Kerkhof A, Nijhof SL.
  Non-pharmacological options for managing chronic musculoskeletal pain in children with pediatric rheumatic disease: a systematic review.
  Rheumatol Int. 2018 Aug 23. doi: 10.1007/s00296-018-4136-8. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/30155667
• Higgins GC.
  Complications of Treatments for Pediatric Rheumatic Diseases.
  Pediatr Clin North Am. 2018 Aug;65(4):827-854. doi: 10.1016/j.pcl.2018.04.008.
  https://www.ncbi.nlm.nih.gov/pubmed/30031500

• Horneff G, Seyger MMB, Arikan D, Kalabic J, Anderson JK, Lazar A, Williams DA, Wang C, Tarzynski-Potempa R, Hyams JS.
  Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.
  J Pediatr. 2018 Jul 25. pii: S0022-3476(18)30755-8. doi: 10.1016/j.jpeds.2018.05.042. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/30054164
• Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J.
  Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis.
  Arch Dis Child. 2018 Jul 19. pii: archdischild-2018-315060. doi: 10.1136/archdischild-2018-315060. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/30026253
• Ferrara G, Mastrangelo G, Barone P, La Torre F, Martino S, Pappagallo G, Ravelli A, Taddio A, Zulian F, Cimaz R; Rheumatology Italian Study Group
  Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.
  Pediatr Rheumatol Online J. 2018 Jul 11;16(1):46. doi: 10.1186/s12969-018-0255-8.
  https://www.ncbi.nlm.nih.gov/pubmed/29996864
• Bharucha KN, Brunner HI, Calvo Penadés I, Nikishina I, Rubio-Pérez N, Oliveira S, Kobusinska K, Schmeling H, Sztajnbok F, Weller-Heinemann F, Zholobova E, Zulian F, Allen R, Chaitow J, Frane J, Wells C, Ruperto N, De Benedetti F; Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group.
  Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial.
  J Rheumatol. 2018 Aug;45(8):1173-1179. doi: 10.3899/jrheum.170326. Epub 2018 Jul 1.
  https://www.ncbi.nlm.nih.gov/pubmed/29961686

• Lovell DJ, Dare JA, Francis-Sedlak M, Ball J, LaMoreaux BD, Von Scheven E, Reinhardt A, Jerath R, Alpan O, Gupta R, Goldsmith D, Zeft A, Naddaf H, Gottlieb B, Jung L, Holt RJ.
  A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.
  Pediatr Rheumatol Online J. 2018 Jun 26;16(1):41. doi: 10.1186/s12969-018-0260-y
  https://www.ncbi.nlm.nih.gov/pubmed/29941047
• Saint-Georges V, Peternel S, Kaštelan M, Brajac I.
  Tumor Necrosis Factor Antagonists in the Treatment of Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH) Syndrome.
  Acta Dermatovenerol Croat. 2018 Jun;26(2):173-178
  https://www.ncbi.nlm.nih.gov/pubmed/29989876
• Emmi G, Urban ML, Imazio M, Gattorno M, Maestroni S, Lopalco G, Cantarini L, Prisco D, Brucato A.
  Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.
  Curr Cardiol Rep. 2018 Jun 14;20(8):61. doi: 10.1007/s11886-018-1007-6
  https://www.ncbi.nlm.nih.gov/pubmed/29904899
• Xu C, Peng H, Li R, Chai W, Li X, Fu J, Liu K, Yu B, Jia C, Chen J.
  Risk factors and clinical characteristics of deep knee infection in patients with intra-articular injections: A matched retrospective cohort analysis.
  Semin Arthritis Rheum. 2018 Jun;47(6):911-916. doi: 10.1016/j.semarthrit.2017.10.013
  https://www.ncbi.nlm.nih.gov/pubmed/29129326
• Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R.
  JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
  J Clin Invest. 2018 Jun 11. pii: 98814. doi: 10.1172/JCI98814
  https://www.ncbi.nlm.nih.gov/pubmed/29649002
• Brucato A, Emmi G, Cantarini L, Di Lenarda A, Gattorno M, Lopalco G, Marcolongo R, Imazio M, Martini A, Prisco D.
  Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism.
  Intern Emerg Med. 2018 Jun;13(4):475-489. doi: 10.1007/s11739-018-1842-x
  https://www.ncbi.nlm.nih.gov/pubmed/29633070

• Ringold S, Nigrovic PA, Feldman BM, Tomlinson GA, von Scheven E, Wallace CA, Huber AM, Schanberg LE, Li SC, Weiss PF, Fuhlbrigge RC, Morgan EM, Kimura Y.
  The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans: Toward Comparative Effectiveness in the Pediatric Rheumatic Diseases.
  Arthritis Rheumatol. 2018 May;70(5):669-678. doi: 10.1002/art.40395. Epub 2018 Mar 31.
  https://www.ncbi.nlm.nih.gov/pubmed/29333701
• Poddighe D, Romano M, Gattinara M, Gerloni V.
  Biologics for the treatment of Juvenile Idiopathic Arthritis.
  Curr Med Chem. 2018 May 21. doi: 10.2174/0929867325666180522085716. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/29788871
• De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Koné-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G.
  Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
  N Engl J Med. 2018 May 17;378(20):1908-1919. doi: 10.1056/NEJMoa1706314.
  https://www.ncbi.nlm.nih.gov/pubmed/29768139
• Yazılıtaş F, Aydoğ Ö, Özlü SG, Çakıcı EK, Güngör T, Eroğlu FK, Gür G, Bülbül M.
  Canakinumab treatment in children with familial Mediterranean fever: report from a single center
  Rheumatol Int. 2018 May;38(5):879-885. doi: 10.1007/s00296-018-3993-5. Epub 2018 Feb 15.
  https://www.ncbi.nlm.nih.gov/pubmed/29450637
• Yildirim T, Yilmaz R, Uzerk Kibar M, Erdem Y.
  Canakinumab treatment in renal transplant recipients with familial Mediterranean fever.
  J Nephrol. 2018 Jun;31(3):453-455. doi: 10.1007/s40620-018-0475-5. Epub 2018 Feb 14.
  https://www.ncbi.nlm.nih.gov/pubmed/29446001
• Poddighe D, Romano M, Gattinara M, Gerloni V.
  Biologics for the treatment of Juvenile Idiopathic Arthritis.
  Curr Med Chem. 2018 May 21. doi: 10.2174/0929867325666180522085716. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/29788871
• Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, Manna R, Cimaz R, Priori R, Talarico R, de Marchi G, Frassi M, Gallizzi R, Soriano A, Alessio M, Cammelli D, Maggio MC, Gentileschi S, Marcolongo R, La Torre F, Fabiani C, Colafrancesco S, Ricci F, Galozzi P, Viapiana O, Verrecchia E, Pardeo M, Cerrito L, Cavallaro E, Olivieri AN, Paolazzi G, Vitiello G, Maier A, Silvestri E, Stagnaro C, Valesini G, Mosca M, de Vita S, Tincani A, Lapadula G, Frediani B, De Benedetti F, Iannone F, Punzi L, Salvarani C, Galeazzi M, Angotti R, Messina M, Tosi GM, Rigante D, Cantarini L; “Working Group” of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology).
  Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study.
  Clin Rheumatol. 2018 May 17. doi: 10.1007/s10067-018-4119-x. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/29770930

• Opoka-Winiarska V, Żuber Z, Alexeeva E, Chasnyk V, Nikishina I, Dębowska G, Smolewska E.
  Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.
  J Rheumatol. 2018 Apr 15. pii: jrheum.171006. doi: 10.3899/jrheum.171006. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/29654485
• Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Antón J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne P, Morgan EM, Quartier P, Ruperto N, Russo R, Saad-Magalhães C, Sawhney S, Scott C, Shenoi S, Swart JF, Uziel Y, Vastert SJ, Smolen JS.
  Treating juvenile idiopathic arthritis to target: recommendations of an international task force.
  Ann Rheum Dis. 2018 Apr 11. pii: annrheumdis-2018-213030. doi: 10.1136/annrheumdis-2018-213030. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/29643108
• Bielak M, Husmann E, Weyandt N, Haas JP, Hügle B, Horneff G, Neudorf U, Lutz T, Lilienthal E, Kallinich T, Tenbrock K, Berendes R, Niehues T, Wittkowski H, Weißbarth-Riedel E, Heubner G, Oommen P, Klotsche J, Foell D, Lainka E.
  IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).
  Pediatr Rheumatol Online J. 2018 Apr 5;16(1):22. doi: 10.1186/s12969-018-0236-y.
  https://www.ncbi.nlm.nih.gov/pubmed/29622022
• Chen Y, Zou K, Sun J, Yang Y, Liu G.
  Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis.
  Pharmacogenomics. 2018 Apr;19(6):529-538. doi: 10.2217/pgs-2017-0208. Epub 2018 Mar 28.
  https://www.ncbi.nlm.nih.gov/pubmed/29589488
• M F Silva J, Ladomenou F, Carpenter B, Chandra S, Sedlacek P, Formankova R, Grandage V, Friswell M, Cant AJ, Nademi Z, Slatter MA, Gennery AR, Hambleton S, Flood TJ, Lucchini G, Chiesa R, Rao K, Amrolia PJ, Brogan P, Wedderburn LR, Glanville JM, Hough R, Marsh R, Abinun M, Veys P.
  Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis.
  Blood Adv. 2018 Apr 10;2(7):777-786. doi: 10.1182/bloodadvances.2017014449.
  https://www.ncbi.nlm.nih.gov/pubmed/29618462
• Ringold S, Nigrovic PA, Feldman BM, Tomlinson GA, von Scheven E, Wallace CA, Huber AM, Schanberg LE, Li SC, Weiss PF, Fuhlbrigge RC, Morgan EM, Kimura Y.
  The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans: Toward Comparative Effectiveness in the Pediatric Rheumatic Diseases.
  Arthritis Rheumatol. 2018 May;70(5):669-678. doi: 10.1002/art.40395. Epub 2018 Mar 31.
  https://www.ncbi.nlm.nih.gov/pubmed/29333701

• Marino A, Real-Fernández F, Rovero P, Giani T, Pagnini I, Cimaz R, Simonini G.
  Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations.
  Clin Rheumatol. 2018 Mar 5. doi: 10.1007/s10067-018-4057-7. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/29508177
• Chen Y, Zou K, Sun J, Yang Y, Liu G.
  Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis.
  Pharmacogenomics. 2018 Mar 28. doi: 10.2217/pgs-2017-0208. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/29589488
• Yasuoka R, Iwata N, Abe N, Kohagura T, Nakaseko H, Shimizu M, Kawabe S.
  Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis.
  Mod Rheumatol. 2018 Mar 26:1-12.
  https://www.ncbi.nlm.nih.gov/pubmed/29578355
• Rubbert-Roth A, Furst DE, Nebesky JM, Jin A, Berber E.
  A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.
  Rheumatol Ther. 2018 Mar 3. doi: 10.1007/s40744-018-0102-x. [Epub ahead of print] 
  https://www.ncbi.nlm.nih.gov/pubmed/29502236
• Okihiro A, Hasija R, Fung L, Cameron B, Feldman BM, Laxer R, Schneider R, Silverman E, Spiegel L, Yeung RSM, Tse SML.
  Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study.
  Pediatr Rheumatol Online J. 2018 Mar 14;16(1):17.
  https://www.ncbi.nlm.nih.gov/pubmed/29540190
• Bhat T, Coughlin CC.
  Mood changes with methotrexate therapy for dermatologic disease.
  Pediatr Dermatol. 2018 Mar;35(2):253-254.
  https://www.ncbi.nlm.nih.gov/pubmed/29315793

• Schoemaker CG, van Dijkhuizen EHP, Vastert SJ.
  Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients
  Pediatr Rheumatol Online J. 2018 Feb 15;16(1):13. doi: 10.1186/s12969-018-0229-x.
  https://www-ncbi-nlm-nih-gov/pubmed/29448947
• Höfel L, Eppler B, Storf M, Schnöbel-Müller E, Haas JP, Hügle B.
  Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing - treatment protocol and preliminary results
  Pediatr Rheumatol Online J. 2018 Feb 13;16(1):11. doi: 10.1186/s12969-018-0228-y.
  https://www-ncbi-nlm-nih-gov/pubmed/29433504
• Beukelman T, Xie F, Chen L, Horton DB, Lewis JD, Mamtani R, Mannion MM, Saag KG, Curtis JR.
  Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors
  Ann Rheum Dis. 2018 Feb 9. pii: annrheumdis-2017-212613. doi: 10.1136/annrheumdis-2017-212613
  https://www-ncbi-nlm-nih-gov/pubmed/29440001
• Klotsche J, Minden K, Niewerth M, Horneff G.
  Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
  Ann Rheum Dis. 2018 Feb 16. pii: annrheumdis-2017-211968. doi: 10.1136/annrheumdis-2017-211968. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/29453217
• Albert D.
  Prescribing for Children with Rheumatic Disease: Perceived Treatment Approaches between Pediatric and Adult Rheumatologists.
  Arthritis Care Res (Hoboken). 2018 Feb 26. doi: 10.1002/acr.23552. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/29481725
• Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ.
  Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
  Ann Rheum Dis. 2018 Feb 22. pii: annrheumdis-2017-212608. doi: 10.1136/annrheumdis-2017-212608. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/29472362

• Lee WJ, Lee TA, Suda KJ, Calip GS, Briars L, Schumock GT.
  Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.
  Rheumatology (Oxford). 2018 Feb 1;57(2):273-282. doi: 10.1093/rheumatology/kex049.
  https://www.ncbi.nlm.nih.gov/pubmed/28431162

• Gadina M, Gazaniga N, Vian L, Furumoto Y.
  Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.
  J Autoimmun. 2017 Dec;85:20-31.
  https://www.ncbi.nlm.nih.gov/pubmed/28676205

• Moghadam-Kia S, Aggarwal R, Oddis CV.
  Biologics for idiopathic inflammatory myopathies.
  Curr Opin Rheumatol. 2017 Nov;29(6):645-651
  https://www.ncbi.nlm.nih.gov/pubmed/28817464
• Horneff G, Peitz J, Kekow J, Foell D.
  Canakinumab for first line steroid-free treatment in a child with systemic-onset juvenile idiopathic arthritis.
  Scand J Rheumatol. 2017 Nov;46(6):500-501
  https://www.ncbi.nlm.nih.gov/pubmed/28266235
• Correll CK, Bullock DR, Cafferty RM, Vehe RK.
  Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.
  Clin Rheumatol. 2017 Nov 4
  https://www.ncbi.nlm.nih.gov/pubmed/29103180
• Langley RG, Kasichayanula S, Trivedi M, Aras GA, Kaliyaperumal A, Yuraszeck T, Gibbs J, Gibbs M, Kricorian G, Paller AS.
  Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis.
  J Clin Pharmacol. 2017 Nov 6
  https://www.ncbi.nlm.nih.gov/pubmed/29106714
• Stoll ML, Grubbs JA, Beukelman T, Mannion ML, Jester TW, Cron RQ, Crain MJ.
  Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study.
  Pediatr Rheumatol Online J. 2017 Nov 9;15(1):79
  https://www.ncbi.nlm.nih.gov/pubmed/29121953

• Mittal L, Zhang L, Feng R, Werth VP.
  Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study.
  J Am Acad Dermatol. 2017 Oct 5. pii: S0190-9622(17)32466-0. doi: 10.1016/j.jaad.2017.09.061. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/28989103

• Murias S, Magallares L, Albizuri F, Pascual-Salcedo D, Dreesen E, Mulleman D.
  Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.
  Ther Drug Monit. 2017 Aug;39(4):370-378. doi: 10.1097/FTD.0000000000000423.
  https://www.ncbi.nlm.nih.gov/pubmed/28703718

• Ahmet A, Brienza V, Tran A, Lemieux J, Aglipay M, Barrowman N, Duffy C, Roth J, Jurencak R.
  Frequency and Duration of Adrenal Suppression Following Glucocorticoid Therapy in Children With Rheumatic Diseases.
  Arthritis Care Res (Hoboken). 2017 Aug;69(8):1224-1230. doi: 10.1002/acr.23123. Epub 2017 Jul 10.
  https://www.ncbi.nlm.nih.gov/pubmed/27723273

• Zhang Y, Milojevic D.
  Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.
  Paediatr Drugs. 2017 Jun;19(3):193-211.
  https://www.ncbi.nlm.nih.gov/pubmed/28290112
• López-Ferrer A, Laiz A, Puig L.
  The safety of ustekinumab for the treatment of psoriatic arthritis.
  Expert Opin Drug Saf. 2017 Jun;16(6):733-742.
  https://www.ncbi.nlm.nih.gov/pubmed/28441904
• Falvey S, Shipman L, Ilowite N, Beukelman T.
  Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis.
  Pediatr Rheumatol Online J. 2017 Jun 19;15(1):52
  https://www.ncbi.nlm.nih.gov/pubmed/28629458
• Ledingham J, Gullick N, Irving K, Gorodkin R, Aris M, Burke J, Gordon P, Christidis D, Galloway S, Hayes E, Jeffries A, Mercer S, Mooney J, van Leuven S, Galloway J; BSR and BHPR Standards, Guidelines and Audit Working Group.
  BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs.
  Rheumatology (Oxford). 2017 Jun 1;56(6):865-868.
  https://www.ncbi.nlm.nih.gov/pubmed/28339817
• Kossi S, Dadoun S, Geri G, Hermet A, Fautrel B, Dougados M, Gossec L.
  Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long-term follow-up of 25 patients.
  Rheumatology (Oxford). 2017 Jun 1;56(6):896-900.
  https://www.ncbi.nlm.nih.gov/pubmed/28073957
• Bragnes Y, Boshuizen R, de Vries A, Lexberg Å, Østensen M.
  Low level of Rituximab in human breast milk in a patient treated during lactation.
  Rheumatology (Oxford). 2017 Jun 1;56(6):1047-1048.
  https://www.ncbi.nlm.nih.gov/pubmed/28339781
• Chausset A, Fargeix T, Pereira B, Echaubard S, Duquesne A, Desjonquères M, Freychet C, Belot A, Merlin E.
  MISS questionnaire in French version: a good tool for children and parents to assess methotrexate intolerance.
  Clin Rheumatol. 2017 Jun;36(6):1281-1288
  https://www.ncbi.nlm.nih.gov/pubmed/28477218
• Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, Mcalindon T.
  2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
  Arthritis Care Res (Hoboken). 2017 Jun 6 doi: 10.1002/acr.23279. [ [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/28585410

• Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-Pérez N, Keltsev V, Kingsbury DJ, Del Rocio Maldonado Velázquez M, Nikishina I, Silverman ED, Joos R, Smolewska E, Bandeira M, Minden K, van Royen-Kerkhof A, Emminger W, Foeldvari I, Lauwerys BR, Sztajnbok F, Gilmer KE, Xu Z, Leu JH, Kim L, Lamberth SL, Loza MJ, Lovell D, Martini A.
  Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
  Ann Rheum Dis. 2017 May 15. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28507219
• Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, Mcalindon T.
  2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
  Arthritis Care Res (Hoboken). 2017 Jun 6. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28585410
• Gentileschi S, Rigante D, Vitale A, Sota J, Frediani B, Galeazzi M, Cantarini L.
  Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.
  Clin Rheumatol. 2017 May 23. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28536823
• Komaki Y, Yamada A, Komaki F, Kudaravalli P, Micic D, Ido A, Sakuraba A.
  Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
  J Autoimmun. 2017 May;79:4-16. doi: 10.1016/j.jaut.2017.02.003.
  https://www.ncbi.nlm.nih.gov/pubmed/?term=28209290
• Goodman DM.
  Pediatric clinical trials-number needed to recruit.
  J Pediatr. 2017 May;184:1-2. doi: 10.1016/j.jpeds.2017.03.011.
  https://www.ncbi.nlm.nih.gov/pubmed/?term=28434563
• Stefanska AM, Distlerová D, Musaus J, Olski TM, Dunder K, Salmonson T, Mentzer D, Müller-Berghaus J, Hemmings R, Veselý R.
  Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.
  Arch Dis Child. 2017 May 29. [Epub ahead of print] Review.
  https://www.ncbi.nlm.nih.gov/pubmed/28554892

• Mauro A, Rigante D, Cimaz R.
  Investigational drugs for treatment of juvenile idiopathic arthritis
  Expert Opin Investig Drugs. 2017 Apr;26(4):381-387. doi: 10.1080/13543784.2017.1301929. Epub 2017 Mar 12. Review.
  https://www.ncbi.nlm.nih.gov/pubmed/28277884

• Scott LJ.
  Sarilumab: First Global Approval.
  Drugs. 2017 Apr;77(6):705-712.
  https://www.ncbi.nlm.nih.gov/pubmed/28290137
• Roszkiewicz J, Smolewska E.
  In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis-Are We Getting Closer to Personalised Medicine?
  Curr Rheumatol Rep. 2017 Apr;19(4):19. doi: 10.1007/s11926-017-0646-8
  https://www.ncbi.nlm.nih.gov/pubmed/28361333
• Zhang X, Chen YC, Terao K.
  Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis.
  Expert Rev Clin Pharmacol. 2017 Mar 15:1-12. doi: 10.1080/17512433.2017.1300058. [Epub ahead of print]
  https://www.ncbi.nlm.nih.gov/pubmed/28293968
• Lee M, Isaacs J.
  The novel use of combined IL-1 and IL-6 inhibition in a patient with severe, aggressive, erosive, systemic-onset juvenile idiopathic arthritis.
  Eur J Rheumatol. 2017 Mar;4(1):68-69. doi: 10.5152/eurjrheum.2016.055.
  https://www.ncbi.nlm.nih.gov/pubmed/28293458

• Nakamura H, Sugai T, Kato M, Hatanaka KC, Atsumi T
  Subcutaneous panniculitis-like T-cell lymphoma with haemophagocytic syndrome during tocilizumab therapy for juvenile idiopathic arthritis.
  Clin Exp Rheumatol. 2017 Jan-Feb;35(1):174. Epub 2017 Jan 5.
  https://www.ncbi.nlm.nih.gov/pubmed/28079502

• Scheuern A1, Tyrrell PN2, Haas JP1, Hügle B3.
  Countermeasures against methotrexate intolerance in juvenile idiopathic arthritis instituted by parents show no effect.
  Rheumatology (Oxford). 2017 Jan 24. pii: kew507. doi: 10.1093/rheumatology/kew507. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28122960
• Brachat AH, Grom AA, Wulffraat N, Brunner HI, Quartier P, Brik R, McCann L, Ozdogan H, Rutkowska-Sak L, Schneider R, Gerloni V, Harel L, Terreri M, Houghton K, Joos R, Kingsbury D, Lopez-Benitez JM, Bek S, Schumacher M, Valentin MA, Gram H, Abrams K, Martini A, Lovell DJ, Nirmala NR, Ruperto N; Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
  Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.
  Arthritis Res Ther. 2017 Jan 23;19(1):13. doi: 10.1186/s13075-016-1212-x.
  https://www.ncbi.nlm.nih.gov/pubmed/28115015

• Lakhanpal A, Brahn E.
  Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions.
  Clin Rheumatol. 2016 Dec;35(12):2869-2875.
  https://www.ncbi.nlm.nih.gov/pubmed/27714482
• Windschall D, Horneff G.
  Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
  Clin Rheumatol. 2016 Dec;35(12):2925-2931.
  https://www.ncbi.nlm.nih.gov/pubmed/27709443 
• Verazza S, Davì S, Consolaro A, Bovis F, Insalaco A, Magni-Manzoni S, Nicolai R, Marafon DP, De Benedetti F, Gerloni V, Pontikaki I, Rovelli F, Cimaz R, Marino A, Zulian F, Martini G, Pastore S, Sandrin C, Corona F, Torcoletti M, Conti G, Fede C, Barone P, Cattalini M, Cortis E, Breda L, Olivieri AN, Civino A, Podda R, Rigante D, La Torre F, D'Angelo G, Jorini M, Gallizzi R, Maggio MC, Consolini R, De Fanti A, Muratore V, Alpigiani MG, Ruperto N, Martini A, Ravelli A; Italian Pediatric Rheumatology Study Group.
  Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
  Pediatr Rheumatol Online J. 2016 Dec 20;14(1):68.
  https://www.ncbi.nlm.nih.gov/pubmed/27993144

• Harrington J, Holmyard D, Silverman E, Sochett E, Grynpas M.
  Bone histomorphometric changes in children with rheumatic disorders on chronic glucocorticoids.
  Pediatr Rheumatol Online J. 2016 Nov 10;14(1):58.
  https://www.ncbi.nlm.nih.gov/pubmed/27832795

• McDonagh JE, Shaw KL, Prescott J, Smith FJ, Roberts R, Gray NJ.
  "Sometimes I feel like a pharmacist": identity and medication use among adolescents with juvenile arthritis.
  Pediatr Rheumatol Online J. 2016 Oct 19;14(1):57.
  https://www.ncbi.nlm.nih.gov/pubmed/27756328

• Koenders MI, van den Berg WB.
  Secukinumab for rheumatology: development and its potential place in therapy.
  Drug Des Devel Ther. 2016 Jun 24;10:2069-80.
  http://www.ncbi.nlm.nih.gov/pubmed/27445458

• Davies HD; COMMITTEE ON INFECTIOUS DISEASES.
  Infectious Complications With the Use of Biologic Response Modifiers in Infants and Children.
  Pediatrics. 2016 Aug;138(2). pii: e20161209. doi: 10.1542/peds.2016-1209. Epub 2016 Jul 18.
  http://www.ncbi.nlm.nih.gov/pubmed/27432853
• Orrock JE, Ilowite NT.
  Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
  Expert Rev Clin Pharmacol. 2016 Aug;9(8):1015-24. doi: 10.1080/17512433.2016.1204910. Epub 2016 Jul 6.
  http://www.ncbi.nlm.nih.gov/pubmed/27367267

• Fráňová J, Fingerhutová Š, Kobrová K, Srp R, Němcová D, Hoza J, Uher M, Saifridová M, Linková L, Doležalová P.
  Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration.
  Pediatr Rheumatol Online J. 2016 Jun 14;14(1):36. doi: 10.1186/s12969-016-0099-z
  http://www.ncbi.nlm.nih.gov/pubmed/27301536
• Sterba Y, Ilowite N.
  Biologics in Pediatric Rheumatology: Quo Vadis?
  Curr Rheumatol Rep. 2016 Jul;18(7):45. doi: 10.1007/s11926-016-0593-9
  http://www.ncbi.nlm.nih.gov/pubmed/27306623

• Kahlenberg JM
  Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade.
  Curr Opin Rheumatol 2016;28(3):197-203. doi: 10.1097/BOR.0000000000000266
  http://www.ncbi.nlm.nih.gov/pubmed/26859478
• Goel N, Chance K.
  Biosimilars in rheumatology: understanding the rigor of their development.
  Rheumatology first published online May 30, 2016. doi: 10.1093/rheumatology/kew206
  http://rheumatology.oxfordjournals.org/content/early/2016/05/28/rheumatology.kew206.abstract
• Ding HJ, Denniston AK, Rao VK, Gordon C.
  Hydroxychloroquine-related retinal toxicity.
  Rheumatology 2016; 55 (6): 957-967. doi: 10.1093/rheumatology/kev357
  http://rheumatology.oxfordjournals.org/content/55/6/968.abstract

• Pagnini I, Bertini F, Cimaz R.
  Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.
  Paediatr Drugs. 2016 Apr;18(2):101-8. doi: 10.1007/s40272-016-0164-6.
  http://www-ncbi-nlm-nih-gov.sire.ub.edu/pubmed/26939782

• Turnier JL, Brunner HI.
  Tocilizumab for treating juvenile idiopathic arthritis.
  Expert Opin Biol Ther. 2016 Apr;16(4):559-66. doi: 10.1517/14712598.2016.1150997
  http://www.ncbi.nlm.nih.gov/pubmed/26848760
• Olech E.
  Biosimilars: Rationale and current regulatory landscape.
  Semin Arthritis Rheum. 2016 Jan 21. pii: S0049-0172(16)00027-5. doi: 10.1016/j.semarthrit.2016.01.001.
  http://www.ncbi.nlm.nih.gov/pubmed/26947438
• Katsicas MM, Russo R.
  Biologic agents in juvenile spondyloarthropathies.
  Pediatr Rheumatol Online J. 2016 Mar 12;14(1):17. doi: 10.1186/s12969-016-0076-6
  http://www.ncbi.nlm.nih.gov/pubmed/26968522

• Nguyen TA, Celano NJ, Matiz C.
  Palisaded Neutrophilic Granulomatous Dermatitis in a Child with Juvenile Idiopathic Arthritis on Etanercept.
  Pediatr Dermatol. 2016 Mar;33(2):e156-7. doi: 10.1111/pde.12797. Epub 2016 Feb 10.
  http://www.ncbi.nlm.nih.gov/pubmed/26860064
• Taddio A, Cattalini M, Simonini G, Cimaz R.
  Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.
  Expert Rev Clin Immunol. 2016 Feb 19:1-9. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26809126
• Lopalco G, Rigante D, Giannini M, Galeazzi M, Lapadula G, Iannone F, Cantarini L.
  Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders.
  Clin Exp Rheumatol. 2016 Feb 26. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26940286

• Calzada-Hernández J, Anton-López J, Bou-Torrent R, Iglesias-Jiménez E, Ricart-Campos S, Martín de Carpi J; Carmen García de Vicuña Muñoz de la Nava, Torrente-Segarra V, Sánchez-Manubens J, Giménez-Roca C, Rozas-Quesada L, Juncosa-Morros MT, Fortuny C, Noguera-Julian A.
  Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.
  Pediatr Rheumatol Online J. 2015 Dec 3;13(1):54. doi: 10.1186/s12969-015-0054-4.
  http://www.ncbi.nlm.nih.gov/pubmed/26635208
• Vaz JL, Fernandes V, Nogueira F, Arnóbio A, Levy RA.
  Infliximab-induced autoantibodies: a multicenter study.
  Clin Rheumatol. 2015 Dec 17.
  http://www.ncbi.nlm.nih.gov/pubmed/26676808
• Hügle B, Horneff G.
  The Role of Synthetic Drugs in the Biologic Era: Therapeutic Strategies for Treating Juvenile Idiopathic Arthritis.
  Expert Opin Pharmacother. 2015 Dec 17.
  http://www.ncbi.nlm.nih.gov/pubmed/26678914

• Agapitos Patakas, Rui-Ru Ji, William Weir, Sean E. Connolly, Robert A. Benson, Steven G. Nadler, James M Brewer, Iain B McInnes and Paul Garside
  Abatacept inhibits T cell priming by inducing of a unique transcriptional profile that reduces their ability to activate antigen presenting cells
  Arthritis & Rheumatology
  DOI: 10.1002/art.39470
  Abstract
• Doyt L. Conn
  Is the Availability of Delayed Release Prednisone an Important Clinical Advance?
  Arthritis Care & Research
  DOI: 10.1002/acr.22745
  Abstract
• Matthew Laurence Stoll, Yoginder Nath Vaid, Saurabh Guleria, Timothy Beukelman, Peter Daniel Waite, and Randy Quentin Cron
  Magnetic Resonance Imaging Findings following Intraarticular Infliximab Therapy for Refractory Temporomandibular Joint Arthritis among Children with Juvenile Idiopathic Arthritis
  J Rheumatol November 2015 42(11):2155-2159; doi:10.3899/jrheum.150308
  Abstract
• Anna Felis-Giemza and Robert J. Moots
  Measurement of anti-drug antibodies to biologic drugs
  Rheumatology (2015) 54 (11): 1941-1943 doi:10.1093/rheumatology/kev279
  Extract
• Tania S. Amin, Sian Shenton, Kathleen Mulligan, Lucy R. Wedderburn, Mark Wood, Vanessa VanRooyen, and Valentina Leone
  Strategies for the prevention and management of methotrexate-related nausea and vomiting in juvenile idiopathic arthritis: results of a UK Paediatric Rheumatology prescriber survey
  Rheumatology (2015) 54 (11): 2108-2109 doi:10.1093/rheumatology/kev259
  Extract

• Hawwa AF, AlBawab A, Rooney M, Wedderburn LR, Beresford MW, McElnay JC.
  Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study
  Arthritis Res Ther. 2015 Oct 22;17(1):295.
  http://www.ncbi.nlm.nih.gov/pubmed/26493320
• Horneff G.
  Biologic-Associated Infections in Pediatric Rheumatology
  Curr Rheumatol Rep. 2015 Nov;17(11):66. doi: 10.1007/s11926-015-0542-z.
  http://www.ncbi.nlm.nih.gov/pubmed/26385753 
• Ding HJ, Denniston AK, Rao VK, Gordon C.
  Hydroxychloroquine-related retinal toxicity
  Rheumatology (Oxford). 2015 Oct 1. pii: kev357. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26428520

• Rondeau JM, Ramage P, Zurini M, Gram H.
  The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.
  MAbs. 2015 Aug 18:0. EPUB ahead of print]
  http://www.ncbi.nlm.nih.gov/pubmed/26284424

• Horneff G
  Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.
  Expert Opin Drug Saf. 2015 Jul;14(7):1111-26. doi: 10.1517/14740338.2015.1042453.
  http://www.ncbi.nlm.nih.gov/pubmed/26084637

• Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH.
  Rituximab for IgG4-related disease: a prospective, open-label trial.
  Ann Rheum Dis. 2015 Jun;74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605.
  http://www.ncbi.nlm.nih.gov/pubmed/25667206
•  Mercer LK, Lunt M, Low AL, Dixon WG, Watson KD, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium.
  Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
  Ann Rheum Dis. 2015 Jun;74(6):1087-93. doi: 10.1136/annrheumdis-2013-204851.
  http://www.ncbi.nlm.nih.gov/pubmed/24685910
•  Scheinberg M.
  Therapy: Facing up to biosimilar agents-the ACR position.
  Nat Rev Rheumatol. 2015 Jun;11(6):322-4. doi: 10.1038/nrrheum.2015.57.
  http://www.ncbi.nlm.nih.gov/pubmed/25907701

• Hermine I Brunner, Nicolino Ruperto, Zbigniew Zuber, Caroline Keane, Olivier Harari, Andrew Kenwright, et al for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
  Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
  Ann Rheum Dis. 2015;74:1110-1117 doi:10.1136/annrheumdis-2014-205351
  http://ard.bmj.com/content/74/6/1110.abstract

• Ilaria Pagnini, Tommaso Bondi, Gabriele Simonini, Teresa Giani, Achille Marino, and Rolando Cimaz
  Successful treatment with canakinumab of a paediatric patient with resistant Behçet’s disease
  Rheumatology first published online May 19, 2015
  doi:10.1093/rheumatology/kev197
  http://rheumatology.oxfordjournals.org/content/early/2015/05/19/rheumatology.kev197.extract

• Bulatović Ćalasan M, Vastert SJ, Scholman RC, Verweij F, Klein M, Wulffraat NM, Prakken BJ, van Wijk F.
  Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis
  Rheumatology (Oxford). 2015 Apr 14. pii: kev101. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25877908

• Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, Touitou I, Koné-Paut I; MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on the behalf of CRI (Club Rhumatisme et Inflammation).
  Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
  Orphanet J Rare Dis. 2015 Feb 15;10(1):19. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25758134
• Ungprasert P, Srivali N, Wijarnpreecha K, Charoenpong P, Knight EL.
  Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis
  Rheumatology (2015) 54 (4): 736-742. doi:10.1093/rheumatology/keu408
  http://rheumatology.oxfordjournals.org/content/54/4/736.abstract
• Strand V, Burmester GR, Zerbini CAF, Mebus CA, Zwillich SH, Gruben D, Wallenstein GV.
  Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial
  Arthritis Care Res (Hoboken) 2015; 67(4):475-483. DOI: 10.1002/acr.22453
  http://onlinelibrary.wiley.com/doi/10.1002/acr.22453/epdf
• Séïté JF, Hillion S, Harbonnier T, Pers JO.
  Review: intravenous immunoglobulin and B cells: when the product regulates the producer.
  Arthritis Rheumatol. 2015 Mar;67(3):595-603. doi: 10.1002/art.38910
  http://www.ncbi.nlm.nih.gov/pubmed/25303681

• Burnett HF, Ungar WJ, Regier DA, Feldman BM, Miller FA.
  Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritis.
  Value Health. 2014 Dec;17(8):830-7. doi: 10.1016/j.jval.2014.08.2668. Epub 2014 Nov 6.
  http://www.ncbi.nlm.nih.gov/pubmed/25498778
  Präger TM, Meyer P, Rafayelyan S, Minden K, Jost-Brinkmann PG.
  Effect of methotrexate on the mandibular development of arthritic rabbits.
  Eur J Orthod. 2014 Dec 17. pii: cju070. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25518996
• Shimizu M, Hamaguchi Y, Ishikawa S, Ueno K, Yachie A.
  Successful treatment with tocilizumab of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis.
  Mod Rheumatol. 2014 Dec 15:1-2.
  http://www.ncbi.nlm.nih.gov/pubmed/25496406
• Berard RA, Laxer RM.
  Early aggressive therapy for patients with juvenile idiopathic arthritis: are we there yet?
  J Rheumatol. 2014 Dec;41(12):2343-6.
  http://www.ncbi.nlm.nih.gov/pubmed/25452178

• Zhao Y, Wallace C.
  Judicious use of biologicals in juvenile idiopathic arthritis
  Curr Rheumatol Rep. 2014 Nov;16(11):454. doi: 10.1007/s11926-014-0454-3.
  http://www.ncbi.nlm.nih.gov/pubmed/25218736

• Ringold S, Hendrickson A, Abramson L, Beukelman T, Blier PR, Bohnsack J, Chalom EC, Gewanter HL, Gottlieb B, Hollister R, Hsu J, Hudgins A, Ilowite NT, Klein-Gitelman M, Lindsley C, LopezBenitez JM, Lovell DJ, Mason T, Milojevic D, Moorthy LN, Nanda K, Onel K, Prahalad S, Rabinovich CE, Ray L, Rouster-Stevens K, Ruth N, Shishov M, Spalding S, Syed R, Stoll M, Vehe RK, Weiss JE, White AJ, Wallace CA, Sobel RE.
  A novel method to collect medication adverse events in juvenile arthritis: Results from the Childhood Arthritis and rheumatology research alliance enhanced drug safety surveillance project (EDSSP).
  Arthritis Care Res (Hoboken). 2014 Oct 20. doi: 10.1002/acr.22487. [Epub ahead of print]
  http://www.ncbi.nlm.nih.gov/pubmed/25331530 
• Windschall D, Müller T, Becker I, Horneff G.
  Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
  Rheumatol Int. 2014 Sep 11. [Epub ahead of print]
  http://www.ncbi.nlm.nih.gov/pubmed/25208527 
• Schmeling H, Horneff G, Benseler SM, Fritzler MJ.
  Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?
  Nat Rev Rheumatol. 2014 Nov;10(11):682-690. doi: 10.1038/nrrheum.2014.140. Epub 2014 Aug 12. Review.
  http://www.ncbi.nlm.nih.gov/pubmed/25112604 
• Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.
  Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
  Arthritis Rheumatol. 2014 Sep;66(9):2580-9. doi: 10.1002/art.38741.
  http://www.ncbi.nlm.nih.gov/pubmed/24942886 
• K A van Schie, M H Hart, E R de Groot, S Kruithof, L A Aarden, G J Wolbink, T Rispens
  Concise report: The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region
  Ann Rheum Dis Published Online First: 23 October 2014
  doi:10.1136/annrheumdis-2014-206237
  http://ard.bmj.com/content/early/2014/10/23/annrheumdis-2014-206237.abstract

• Mannion ML1, Beukelman T.
  Risk of malignancy associated with biologic agents in pediatric rheumatic disease.
  Curr Opin Rheumatol. 2014 Sep;26(5):538-42.
  http://www.ncbi.nlm.nih.gov/pubmed/25010437

• Mannion ML, Xie F, Curtis JR, Beukelman T.
  Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors.
  J Rheumatol. 2014 Aug 1.
  http://www.ncbi.nlm.nih.gov/pubmed/25086081

• Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, Muscal E, Deiva K, Andersen E, Eyre MR, Eleftheriou D, Brogan PA, Kneen R, Alper G, Anlar B, Wassmer E, Heineman K, Hemingway C, Riney CJ, Kornberg A, Tardieu M, Stocco A, Banwell B, Gorman MP, Benseler SM, Lim M.
  Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
  Neurology. 2014 Jul 8;83(2):142-50
  http://www.ncbi.nlm.nih.gov/pubmed/24920861
• Scott LJ.
  Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases.
  Drugs. 2014 Jul 18. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/25034360
• Dale RC1, Brilot F2, Duffy LV2, Twilt M2, Waldman AT2, Narula S2, Muscal E2, Deiva K2, Andersen E2, Eyre MR2, Eleftheriou D2, Brogan PA2, Kneen R2, Alper G2, Anlar B2, Wassmer E2, Heineman K2, Hemingway C2, Riney CJ2, Kornberg A2, Tardieu M2, Stocco A2, Banwell B2, Gorman MP2, Benseler SM2, Lim M2.
  Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
  Neurology. 2014 Jul 8;83(2):142-50. 
  http://www.ncbi.nlm.nih.gov/pubmed/24920861
• [No authors listed]Discrepancy Between Clinical and Radiological Responses to Tocilizumab Treatment in Patients with Systemic-onset Juvenile Idiopathic Arthritis.
  J Rheumatol. 2014 Jul;41(7):1567.
  http://www.ncbi.nlm.nih.gov/pubmed/24986971
• Windschall D1, Müller T, Becker I, Horneff G.
  Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-relatedarthritis and psoriasis arthritis.
  Clin Rheumatol. 2014 Jul 18.
  http://www.ncbi.nlm.nih.gov/pubmed/25034081
• Sobel RE1, Lovell DJ2, Brunner HI2, Weiss JE3, Morris PW4, Gottlieb BS5, Chalom EC6, Jung LK7, Onel KB8, Petiniot L9, Goldsmith DP10, Nanda K11, Shishov M12, Abramsky S1, Young JP13, Giannini EH2.
  Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry.
  Pediatr Rheumatol Online J. 2014 Jul 16;12:29.
  http://www.ncbi.nlm.nih.gov/pubmed/25034081
• Shimizu M1, Ueno K2, Ishikawa S2, Tokuhisa Y2, Inoue N2, Yachie A2.
  Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus.
  Rheumatology (Oxford). 2014 Jul 26.
  http://www.ncbi.nlm.nih.gov/pubmed/25065006
• Autmizguine J1, Cohen-Wolkowiez M, Ilowite N; for the RAPPORT investigators.
  Rilonacept Pharmacokinetics in Children With Systemic Juvenile Idiopathic Arthritis.
  J Clin Pharmacol. 2014 Jul 30.
  http://www.ncbi.nlm.nih.gov/pubmed/25079592

• Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK.
  Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years.
  J Rheumatol. 2014 May 15. pii: jrheum.131231. [Epub ahead of print]
  http://www.ncbi.nlm.nih.gov/pubmed/24833759
• Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK.
  Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years.
  J Rheumatol. 2014 May 15. pii: jrheum.131231. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24833759

• Santer M, Ring N, Yardley L, Geraghty AW, Wyke S.
  Treatment non-adherence in pediatric long-term medical conditions: systematic review and synthesis of qualitative studies of caregivers' views.
  BMC Pediatr. 2014 Mar 4;14(1):63. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24593304
• Tanaka T, Narazaki M, Ogata A, Kishimoto T.
  A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
  Semin Immunol. 2014 Mar 1. pii: S1044-5323(14)00010-4. doi: 10.1016/j.smim.2014.01.009. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24594001

• Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H.
  Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.
  Clin Rheumatol. 2014 Feb 2. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24487484
• Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H.
  The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.
  Rheumatology (Oxford). 2014 Feb;53(2):213-22. doi: 10.1093/rheumatology/ket260. Epub 2013 Aug 14.
  http://www.ncbi.nlm.nih.gov/pubmed/23946436
• Iannone F, La Montagna G, Bagnato G, Gremese E, Giardina A, Lapadula G.
  Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial.
  J Rheumatol. 2014 Feb;41(2):286-92. doi: 10.3899/jrheum.130658. Epub 2014 Jan 15.
  http://www.ncbi.nlm.nih.gov/pubmed/24429167
• Hashkes PJ, Becker ML, Cabral DA, Laxer RM, Paller AS, Rabinovich CE, Turner D, Zulian F.
  Methotrexate: new uses for an old drug.
  J Pediatr. 2014 Feb;164(2):231-6. doi: 10.1016/j.jpeds.2013.10.029.
  http://www.ncbi.nlm.nih.gov/pubmed/24286573

• Berard RA, Laxer RM.
  Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis.
  Expert Opin Biol Ther. 2013 Nov;13(11):1623-30.
  http://www.ncbi.nlm.nih.gov/pubmed/24070010

• Frampton JE.
  Tocilizumab: A Review of Its Use in the Treatment of Juvenile Idiopathic Arthritis.
  Paediatr Drugs. 2013 Oct 24. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24155139
• Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S,Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI.
  Using Registries to Identify Adverse Events in Rheumatic Diseases.
  Pediatrics.2013 Oct 21. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24144710
• Prince FH, Solomon DH.
  Dosing of biologics in juvenile idiopathic arthritis: is the sky the limit?
  J Rheumatol. 2013 Oct;40(10):1643-5. doi: 10.3899/jrheum.130875.
  http://www.ncbi.nlm.nih.gov/pubmed/2408575

• Ioannidis JP, Karassa FB, Druyts E, Thorlund K, Mills EJ
  Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales.
  Nat Rev Rheumatol 2013 Sep 3. doi: 10.1038/nrrheum.2013.134. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/23999553

• Seror R, Richez C, Sordet C, et al. for the Club Rhumatismes et Inflammation Section of the SFR.
  Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey
  Rheumatology 2013 May; 52:868-74 doi:10.1093/rheumatology/kes375.
  http://rheumatology.oxfordjournals.org/content/52/5/868.abstract